In good agreement with this model, clinico-genomic analysis of 424 G12Ci-treated NSCLC patients revealed that patients with inactivating mutations in KEAP1 exhibited a poor response to G12Ci treatment, characterized by early disease progression (Fig. 2q) [56]. The gene discussed is KEAP1; the disease is non-small cell lung carcinoma.